Traders Buy High Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) saw some unusual options trading on Thursday. Traders acquired 11,316 call options on the company. This is an increase of approximately 214% compared to the typical daily volume of 3,599 call options.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors have recently added to or reduced their stakes in CAPR. Farallon Capital Management LLC bought a new position in Capricor Therapeutics during the 4th quarter worth about $31,056,000. Vanguard Group Inc. grew its holdings in shares of Capricor Therapeutics by 44.4% during the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after buying an additional 700,243 shares in the last quarter. Woodline Partners LP acquired a new stake in Capricor Therapeutics in the 4th quarter valued at approximately $8,693,000. Altium Capital Management LLC lifted its stake in Capricor Therapeutics by 150.5% in the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock valued at $9,853,000 after acquiring an additional 429,000 shares in the last quarter. Finally, Black Diamond Financial LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth approximately $3,833,000. 21.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CAPR has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock opened at $14.36 on Friday. The company has a market capitalization of $652.95 million, a P/E ratio of -13.55 and a beta of 4.10. The business has a 50-day moving average of $14.06 and a two-hundred day moving average of $14.50. Capricor Therapeutics has a 1 year low of $3.52 and a 1 year high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The business had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $9.87 million. On average, equities analysts anticipate that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.